suramin has been researched along with B16 Melanoma in 6 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| " FCE 26644 and suramin, a compound possessing the same terminal half-life (t1/2) in mice and, presumably, the same mode of action, inhibit the growth of solid murine tumors, M5076 reticulosarcoma, and MXT and S180 fibrosarcoma and are inactive against B16F10 melanoma." | 3.69 | Antitumor activity of FCE 26644 a new growth-factor complexing molecule. ( Farao, M; Grandi, M; Marsiglio, A; Mongelli, N; Pesenti, E; Sola, F, 1995) |
| " A dose-response experiment in the B16F10 melanoma model showed that inhibition of lung colony formation was still significant with 50 mg/kg pretreatment, whereas a borderline effect was observed at 10 mg/kg." | 1.29 | Inhibition of lung and liver tumor colonies in mice pretreated with suramin. ( Farao, M; Grandi, M; Mariani, M; Marsiglio, A; Sola, F, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Yamamoto, S | 1 |
| Matsuo, K | 1 |
| Sakai, S | 1 |
| Mishima, I | 1 |
| Hara, Y | 1 |
| Oiso, N | 1 |
| Kawada, A | 1 |
| Yoshie, O | 1 |
| Nakayama, T | 1 |
| Dua, P | 1 |
| Ingle, A | 1 |
| Gude, RP | 1 |
| Garrido, T | 1 |
| Riese, HH | 1 |
| Aracil, M | 1 |
| Pérez-Aranda, A | 1 |
| Sola, F | 2 |
| Farao, M | 2 |
| Pesenti, E | 1 |
| Marsiglio, A | 2 |
| Mongelli, N | 1 |
| Grandi, M | 2 |
| Mariani, M | 1 |
| Nakajima, M | 1 |
| DeChavigny, A | 1 |
| Johnson, CE | 1 |
| Hamada, J | 1 |
| Stein, CA | 1 |
| Nicolson, GL | 1 |
6 other studies available for suramin and B16 Melanoma
| Article | Year |
|---|---|
P2X receptor agonist enhances tumor-specific CTL responses through CD70+ DC-mediated Th17 induction.
Topics: Adenosine Triphosphate; Adjuvants, Vaccine; Animals; CD27 Ligand; Cell Differentiation; Dendritic Ce | 2021 |
Suramin augments the antitumor and antimetastatic activity of pentoxifylline in B16F10 melanoma.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Endothelial cell differentiation into capillary-like structures in response to tumour cell conditioned medium: a modified chemotaxis chamber assay.
Topics: Adenocarcinoma; Animals; Antibodies; Aorta; Breast Neoplasms; Capillaries; Cattle; Cell Differentiat | 1995 |
Antitumor activity of FCE 26644 a new growth-factor complexing molecule.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Distamycins; Drug Administration Schedule; Drug Re | 1995 |
Inhibition of lung and liver tumor colonies in mice pretreated with suramin.
Topics: Animals; Dose-Response Relationship, Drug; Female; Liver Neoplasms; Lung Neoplasms; Lymphoma, Large | 1993 |
Suramin. A potent inhibitor of melanoma heparanase and invasion.
Topics: Animals; Antineoplastic Agents; Chromatography, Gel; Extracellular Matrix; Glucuronidase; Glycoside | 1991 |